Chart Events
Performance Outlook
| Previous Close | 0.3202 |
| Open | 0.3203 |
| Bid | 0.3206 x 1300 |
| Ask | 0.3261 x 1000 |
| Day's Range | 0.3203 - 0.3613 |
| 52 Week Range | 0.2300 - 1.9800 |
| Volume | |
| Avg. Volume | 343,773 |
| Market Cap | 8.41M |
| Beta (5Y Monthly) | 2.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- American City Business Journals
Cancer biotech cuts staff by one-fifth
Boston biotech Oncorus Inc. is losing one-fifth of its employees as it pauses work on all but one drug. Oncorus (Nasdaq: ONCR) announced the cuts on Wednesday, saying it will lay off 20% of its staff. ONCR-021 is still preclinical, but Oncorus believes it could have applications in non-small cell lung cancer, hepatocellular carcinoma, clear cell renal cell carcinoma and melanoma.
- Benzinga
Oncorus Pulls Plug On Phase 1 Candidate, Lays Off 20% Of Its Workforce
Oncorus Inc (NASDAQ: ONCR) is reprioritizing its pipeline and is discontinuing the Phase 1 trial of ONCR-177 to focus resources on ONCR-021. In addition, the company is discontinuing the development of ONCR-177, reducing its workforce and burn rate, and reiterating guidance for its cash runway into early 2024. Oncorus will present the results of the Phase 1 study of ONCR-177 in patients with advanced disease in conjunction with a scientific congress in 2023. Related: Chardan Sees Over 200% Upsid
- Zacks
Oncorus, Inc. (ONCR) Moves to Buy: Rationale Behind the Upgrade
Oncorus, Inc. (ONCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
